{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-041709","form_type":"8-K","ticker":null,"cik":"0000316253","company_name":"ENZO BIOCHEM INC","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.737579+00:00","generated_at":"2026-06-14T18:38:11.456984+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enzo Biochem raises $7M via 10% secured convertible debentures and warrants","bullets":["Issued $7,608,696 principal amount of 10% OID secured convertible debentures for $7,000,000 net proceeds.","Warrants to purchase up to 1,000,000 shares at $2.31/share, exercisable for 5 years.","Debentures mature May 20, 2024; convertible at $3.01/share; interest rises to 18% on default.","Upon sale of Enzo Clinical Labs to LabCorp, company must prepay $4M or deposit cash collateral.","Registration rights agreement requires filing by June 19, 2023; liquidated damages if missed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-041709","json":"https://secwatch.observer/filing/0001213900-23-041709.json","markdown":"https://secwatch.observer/filing/0001213900-23-041709.md","text":"https://secwatch.observer/filing/0001213900-23-041709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/0001213900-23-041709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/ea178994-8k_enzobio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:38:11.456984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c86b5021456a1ae2961fa755be1066b02923d4c8","claim":"ENZO BIOCHEM INC incurred convertible notes of $7,608,696 with JGB Collateral, LLC, as collateral agent for the Purchasers at 10% per annum maturing May 20, 2024.","evidence_excerpt":"the Company agreed to sell to the Purchasers (i) 10% Original Issue Discount Secured Convertible Debentures (the “Debentures”) with an aggregate principal amount of $7,608,696","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/0001213900-23-041709-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$7,608,696"},{"label":"Counterparty","value":"JGB Collateral, LLC, as collateral agent for the Purchasers"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"May 20, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9fde28c93dcc7cb1a05867aab3e77e9cb5c1925b","claim":"ENZO BIOCHEM INC entered into Securities Purchase Agreement with JGB Collateral, LLC, as collateral agent, and the purchasers that are parties thereto valued at aggregate principal amount of $7,608,696 and ... total purchase price of $7,000,000 (effective 2023-05-19).","evidence_excerpt":"On May 19, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers that are parties thereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) and JGB Collateral, LLC, a Delaware limited liability company, as collateral agent for the Purchasers (the “Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/0001213900-23-041709-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"JGB Collateral, LLC, as collateral agent, and the purchasers that are parties thereto"},{"label":"Value","value":"aggregate principal amount of $7,608,696 and ... total purchase price of $7,000,000"},{"label":"Effective","value":"2023-05-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}